| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't
- Language: English
- [Curr Opin Lipidol] 2024 Jun 01; Vol. 35 (3), pp. 141-148. <i>Date of Electronic Publication: </i>2024 Jan 25.
- MeSH Terms: C-Reactive Protein* / metabolism ; Inflammation* / drug therapy ; Diet* ; Humans ; Anti-Inflammatory Agents / therapeutic use ; Anti-Inflammatory Agents / pharmacology
- References: Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study. Lancet 2018; 392:1736–1788. ; Patel KV, Pandey A, de Lemos JA. Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine. Circulation 2018; 137:2551–2553. ; Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377:1119–1131. ; Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020; 383:1838–1847. ; Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019; 381:2497–2505. ; Ridker PM. A test in context: high-sensitivity c-reactive protein. J Am Coll Cardiol 2016; 67:712–723. ; Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 2011; 123:731–738. ; Lane T, Wassef N, Poole S, et al. Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res 2014; 114:672–676. ; Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 2018; 391:319–328. ; Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019; 380:752–762. ; Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res 2016; 118:145–156. ; Blaum C, Brunner FJ, Kroger F, et al. Modifiable lifestyle risk factors and C-reactive protein in patients with coronary artery disease: Implications for an anti-inflammatory treatment target population. Eur J Prev Cardiol 2021; 28:152–158. ; Calder PC, Ahluwalia N, Brouns F, et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr 2011; 106: (Suppl 3): S5–S78. ; Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336:1117–1124. ; Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018; 378:e34. ; Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195–2207. ; Cupido AJ, Kastelein JJP. Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials. Cardiovasc Res 2020; 116:e136–e139. ; Ruscica M, Ferri N, Corsini A, Sirtori CR. PCSK9 antagonists and inflammation. Atherosclerosis 2018; 268:235–236. ; Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 2015; 132:1224–1233. ; Banach M, Duell PB, Gotto AM Jr, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol 2020; 5:1124–1135. ; Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387–2397. ; Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol 2007; 99:805–807. ; Del Giudice E, Sota J, Orlando F, et al. Off-label use of canakinumab in pediatric rheumatology and rare diseases. Front Med (Lausanne) 2022; 9:998281. ; Sehested TSG, Bjerre J, Ku S, et al. Cost-effectiveness of canakinumab for prevention of recurrent cardiovascular events. JAMA Cardiol 2019; 4:128–135. ; Deftereos SG, Beerkens FJ, Shah B, et al. Colchicine in cardiovascular disease: in-depth review. Circulation 2022; 145:61–78. ; Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61:404–410. ; Fiolet ATL, Silvis MJM, Opstal TSJ, et al. Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. PLoS One 2020; 15:e0237665. ; Alam M, Kontopantelis E, Mamas MA, et al. Meta-analysis of the effect of colchicine on C-reactive protein in patients with acute and chronic coronary syndromes. Coron Artery Dis 2023; 34:210–215. ; Hennessy T, Soh L, Bowman M, et al. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J 2019; 215:62–69. ; Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J 2021; 42:2765–2775. ; Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42:3227–3337. ; Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2023; 148:e9–e119. ; Robinson PC, Terkeltaub R, Pillinger MH, et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med 2022; 135:32–38. ; Swarup A, Sachdeva N, Schumacher HR Jr. Dosing of antirheumatic drugs in renal disease and dialysis. J Clin Rheumatol 2004; 10:190–204. ; Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2021; 397:2060–2069. ; Sarwar N, Butterworth AS, Freitag DF, et al. Collaboration IRGCERF. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379:1205–1213. ; Wada Y, Jensen C, Meyer ASP, et al. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol 2023; 82:279–285. ; Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res 2021; 117:e138–e140. ; Clemente-Suarez VJ, Beltran-Velasco AI, Redondo-Florez L, et al. Global impacts of western diet and its effects on metabolism and health: a narrative review. Nutrients 2023; 15:2749. ; Wu H, Flint AJ, Qi Q, et al. Association between dietary whole grain intake and risk of mortality: two large prospective studies in US men and women. JAMA Intern Med 2015; 175:373–384. ; Bay B, Blaum C, Kellner C, et al. Inflammatory burden, lifestyle and atherosclerotic cardiovascular disease: insights from a population based cohort study. Sci Rep 2023; 13:21761. ; Delgado-Lista J, Alcala-Diaz JF, Torres-Pena JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 2022; 399:1876–1885. ; Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344:3–10. ; de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99:779–785. ; Fung TT, Rexrode KM, Mantzoros CS, et al. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation 2009; 119:1093–1100. ; Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003; 348:2599–2608. ; Ciccarone E, Di Castelnuovo A, Salcuni M, et al. A high-score Mediterranean dietary pattern is associated with a reduced risk of peripheral arterial disease in Italian patients with Type 2 diabetes. J Thromb Haemost 2003; 1:1744–1752. ; Ruiz-Canela M, Estruch R, Corella D, et al. Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial. JAMA 2014; 311:415–417. ; Waldeyer C, Brunner FJ, Braetz J, et al. Adherence to Mediterranean diet, high-sensitive C-reactive protein, and severity of coronary artery disease: contemporary data from the INTERCATH cohort. Atherosclerosis 2018; 275:256–261. ; Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289:1799–1804. ; Gambardella J, Santulli G. Integrating diet and inflammation to calculate cardiovascular risk. Atherosclerosis 2016; 253:258–261. ; Estruch R, Martinez-Gonzalez MA, Corella D, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006; 145:1–11. ; Soltani S, Shirani F, Chitsazi MJ, Salehi-Abargouei A. The effect of dietary approaches to stop hypertension (DASH) diet on weight and body composition in adults: a systematic review and meta-analysis of randomized controlled clinical trials. Obes Rev 2016; 17:442–454. ; Saneei P, Salehi-Abargouei A, Esmaillzadeh A, Azadbakht L. Influence of Dietary Approaches to Stop Hypertension (DASH) diet on blood pressure: a systematic review and meta-analysis on randomized controlled trials. Nutr Metab Cardiovasc Dis 2014; 24:1253–1261. ; Shirani F, Salehi-Abargouei A, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH) diet on some risk for developing type 2 diabetes: a systematic review and meta-analysis on controlled clinical trials. Nutrition 2013; 29 (7–8):939–947. ; Belanger MJ, Kovell LC, Turkson-Ocran RA, et al. Effects of the Dietary Approaches to Stop Hypertension Diet on change in cardiac biomarkers over time: results from the DASH-Sodium Trial. J Am Heart Assoc 2023; 12:e026684. ; Makarewicz-Wujec M, Henzel J, Kruk M, et al. DASH diet decreases CXCL4 plasma concentration in patients diagnosed with coronary atherosclerotic lesions. Nutr Metab Cardiovasc Dis 2020; 30:56–59. ; Belfort GP, de Padilha PC, Farias DR, et al. Effect of the Dietary Approaches to Stop Hypertension (DASH) diet on the development of preeclampsia and metabolic outcomes in pregnant women with preexisting diabetes mellitus: a randomised, controlled, single-blind trial. J Nutr Sci 2023; 12:e73. ; Sullivan VK, Appel LJ, Seegmiller JC, et al. A low-sodium DASH dietary pattern affects serum markers of inflammation and mineral metabolism in adults with elevated blood pressure. J Nutr 2021; 151:3067–3074. ; Jahns L, Conrad Z, Johnson LK, et al. A diet high in carotenoid-rich vegetables and fruits favorably impacts inflammation status by increasing plasma concentrations of IFN-alpha2 and decreasing MIP-1beta and TNF-alpha in healthy individuals during a controlled feeding trial. Nutr Res 2018; 52:98–104. ; Soltani S, Chitsazi MJ, Salehi-Abargouei A. The effect of dietary approaches to stop hypertension (DASH) on serum inflammatory markers: a systematic review and meta-analysis of randomized trials. Clin Nutr 2018; 37:542–550. ; Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 2015; 21:263–269. ; Santa-Maria C, Lopez-Enriquez S, Montserrat-de la Paz S, et al. Update on anti-inflammatory molecular mechanisms induced by oleic acid. Nutrients 2023; 15:224. ; McEvoy JW, Nasir K, DeFilippis AP, et al. Relationship of cigarette smoking with inflammation and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2015; 35:1002–1010. ; Thompson G, Davison GW, Crawford J, Hughes CM. Exercise and inflammation in coronary artery disease: a systematic review and meta-analysis of randomised trials. J Sports Sci 2020; 38:814–826. ; Cohen E, Margalit I, Shochat T, et al. Markers of chronic inflammation in overweight and obese individuals and the role of gender: a cross-sectional study of a large cohort. J Inflamm Res 2021; 14:567–573. ; Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117:175–184. ; Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest 2017; 127:1–4. ; Reddy A, Gatta PD, Mason S, et al. Adherence to a Mediterranean diet may improve serum adiponectin in adults with nonalcoholic fatty liver disease: the MEDINA randomized controlled trial. Nutr Res 2023; 119:98–108. ; Georgoulis M, Yiannakouris N, Kechribari I, et al. Sustained improvements in the cardiometabolic profile of patients with obstructive sleep apnea after a weight-loss Mediterranean diet/lifestyle intervention: 12-month follow-up (6 months postintervention) of the ‘MIMOSA’ randomized clinical trial. Nutr Metab Cardiovasc Dis 2023; 33:1019–1028. ; Koelman L, Egea Rodrigues C, Aleksandrova K. Effects of dietary patterns on biomarkers of inflammation and immune responses: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr 2022; 13:101–115. ; Tagliamonte S, Laiola M, Ferracane R, et al. Mediterranean diet consumption affects the endocannabinoid system in overweight and obese subjects: possible links with gut microbiome, insulin resistance and inflammation. Eur J Nutr 2021; 60:3703–3716. ; Wade AT, Davis CR, Dyer KA, et al. Effects of Mediterranean diet supplemented with lean pork on blood pressure and markers of cardiovascular risk: findings from the MedPork trial. Br J Nutr 2019; 122:873–883. ; Mayr HL, Thomas CJ, Tierney AC, et al. Randomization to 6-month Mediterranean diet compared with a low-fat diet leads to improvement in Dietary Inflammatory Index scores in patients with coronary heart disease: the AUSMED Heart Trial. Nutr Res 2018; 55:94–107. ; Rallidis LS, Kolomvotsou A, Lekakis J, et al. Short-term effects of Mediterranean-type diet intervention on soluble cellular adhesion molecules in subjects with abdominal obesity. Clin Nutr ESPEN 2017; 17:38–43. ; Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008; 359:229–241. ; Esposito K, Marfella R, Ciotola M, et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292:1440–1446. ; Juraschek SP, Kovell LC, Appel LJ, et al. Effects of diet and sodium reduction on cardiac injury, strain, and inflammation: the DASH-Sodium Trial. J Am Coll Cardiol 2021; 77:2625–2634. ; Smith PJ, Mabe SM, Sherwood A, et al. Metabolic and neurocognitive changes following lifestyle modification: examination of biomarkers from the ENLIGHTEN Randomized Clinical Trial. J Alzheimers Dis 2020; 77:1793–1803. ; Erlinger TP, Miller ER 3rd, Charleston J, Appel LJ. Inflammation modifies the effects of a reduced-fat low-cholesterol diet on lipids: results from the DASH-sodium trial. Circulation 2003; 108:150–154.
- Substance Nomenclature: 9007-41-4 (C-Reactive Protein) ; 0 (Anti-Inflammatory Agents)
- Entry Date(s): Date Created: 20240126 Date Completed: 20240501 Latest Revision: 20240611
- Update Code: 20240611
|
